RhythMedix has launched its next-generation wearable cardiac monitor that has built-in cellular connectivity.

The Mount Laurel, NJ-based company said its RhythmStar device enables rapid ECG analysis and reporting of cardiac abnormalities by RhythMedix’s team of US-based certified technicians, who alert physicians if an arrhythmia of concern is detected.

RhythmStar is now available with HeartTime on-demand telemetry mode, a platform that allows physicians to evaluate cardiac activity and expedite care via a telemedicine appointment, limiting the need for an in-person office visit, the company said.

“The novel wearable RhythmStar monitoring device offers increased patient compliance and allows for accurate assessment of cardiac rhythm in real time,” said Steven DaTorre, MD, a Clinical Cardiologist at Cooper University Health Care in New Jersey. “It also allows me to remain connected to my patients throughout their monitoring period, which may expedite a life-saving diagnosis.”

ECG Monitoring Market at a Glance According to a report published in August 2020 by Global Market Insights, the market valuation of cardiac arrhythmia monitoring devices will cross $9 billion by 2026.

The report said new product launches with enhanced detection and portability features will spur the market-growth.

Most recently, AliveCor made significant movements in the space – by winning FDA clearance for an expanded range of ECG determinations for the KardiaMobile application. The Mountain View, CA-based company also announced a collaboration with AstraZeneca.

The collaboration will translate AliveCor’s potassium detection technology and science, which enables potassium measurement outside of blood draws, into real-world disease management applications and solutions.

Earlier this week, VivaLNK announced the availability of a wearable monitoring solution designed to wirelessly capture ECG and heart rate during a six-minute walk test.

In recent deal activity in the space, Boston Scientific said it would acquire Minneapolis, MN-based Preventice Solutions, a private company it already held about a 22% stake in, for $925 million-plus the potential of an additional $300 million commercial milestone payment.

That announcement came on the heels of Hillrom announcing its planned acquisition of Seattle, WA-based Bardy Diagnostics (BardyDx) for $375 million. These two deals followed Royal Philips’ mid-December news of a $2.8 billion move to acquire Malvern, PA-based BioTelemetry.

Article source:MDDI Online by Omar Ford